Background:The incidence of cognitive impairment(CI)is gradually increasing,which has attracted more attention from medical researchers worldwide.Definitive mechanisms of pathogenesis remain elusive,and there are few ...Background:The incidence of cognitive impairment(CI)is gradually increasing,which has attracted more attention from medical researchers worldwide.Definitive mechanisms of pathogenesis remain elusive,and there are few medications that have been proven effective for CI.The utilization of Chinese herbal medicine has shown positive therapeutic effects for a broad spectrum of diseases,including CI.Objective:The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules(GLJC,龟龄集胶囊)in treating mild-to-moderate CI with Shen(Kidney)and marrow deficiency syndrome.Methods:This is a randomized,double-blind,positive-controlled,multicenter clinical trial with a noninferiority design that included 348 participants randomly divided into an experimental arm and an active comparator arm.Individuals in the experimental arm(174 cases)took 0.6 g of GLJC once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day.Individuals in the active comparator arm(174 cases)took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day.The intervention period included two sessions over 24 weeks.The primary outcome be the effectiveness of GLJC on cognitive improvement after 24 weeks of treatment,which was defined as an increase in the Mini Mental State Examination(MMSE)and Montreal Cognitive Assessment(MoCA)Scale.The secondary outcomes were improvement in independence,daily living ability,and Chinese medicine(CM)syndrome,which were measured with the Alzheimer’s disease Rating Scale-Cognitive Project(ADAS-Cog),Clinical Dementia Rating(CDR)Total Score,Activities of Daily Living(ADL)Total Score and the Chinese Medicine Symptom Scale(CM-SS),respectively.Serum acetylcholine,acetylcholinesterase,bax and bcl-2 were monitored to explore the mechanism of GLJC on CI.In addition,safety measures,including vital signs,electrocardiography,laboratory indicators(full blood count,kidney and liver function tests,routine urine test and routine stool test)and adverse events,were also recorded.Discussion:The purpose of this trial is to evaluate the efficacy and safety of GLJC in patients with mild-to-moderate CI with kidney and marrow deficiency syndrome.If successful,the results would provide a viable treatment for patients with mild-to-moderate CI.展开更多
Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin i...Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin in AP and IS treatment by target prediction,protein-protein interaction(PPI)data collection,network construction,network analysis,and enrichment analysis.Furthermore,molecular docking simulation was employed to analyze the interaction between scutellarin and core targets.Results:Two networks were established,including a disease-target network and a PPI network of scutellarin targets against AP and IS.Network analysis showed that 14 targets,namely,AKT1,VEGFA,JUN,ALB,MTOR,ESR1,MAPK8,HSP90 AA1,NOS3,SERPINE1,FGA,F2,FOXO3,and STAT1,might be the therapeutic targets of scutellarin in AP and IS.Among them,NOS3 and F2 were recognized as the core targets.Additionally,molecular docking simulation confirmed that scutellarin exhibited a relatively high potential for binding to the active sites of NOS3 and F2.Furthermore,enrichment analysis indicated that scutellarin might exert a therapeutic role in both AP and IS by regulating several important pathways,such as coagulation cascades,mitogen-activated protein kinase(MAPK)signaling pathway,phosphatidylinositol 3 kinase(PI3 K)/protein kinase B(Akt)/mammalian target of rapamycin(m TOR)signaling pathway,Toll-like receptor signaling pathway,hypoxia inducible factor-1(HIF-1)signaling pathway,forkhead box O(Fox O)signaling pathway,tumor necrosis factor(TNF)signaling pathway,adipocytokine signaling pathway,insulin signaling pathway,insulin resistance,and estrogen signaling pathway.Conclusions:The shared underlying mechanisms of scutellarin on AP and IS treatment might be strongly associated with its vasorelaxant,anticoagulant,anti-inflammatory,and antioxidative effects as well as its effect on improving lipid metabolism.展开更多
Ginkgo(Ginkgo biloba L.)is aperennial deciduous tree of the Ginkgoaceae family,and its seeds(ginkgo nut)and leaves have high medicinal values.G.biloba was firstly recorded in Materia Medica in Shaoxin Medica;previous ...Ginkgo(Ginkgo biloba L.)is aperennial deciduous tree of the Ginkgoaceae family,and its seeds(ginkgo nut)and leaves have high medicinal values.G.biloba was firstly recorded in Materia Medica in Shaoxin Medica;previous texts on Materia Medica have mostly listed ginkgo nuts.展开更多
Objective： To evaluate the prognosis effect of Chinese herbal medicines（CHMs） for benefiting qi and activating blood circulation adjunctive to conventional treatment in patients with acute coronary syndrome（ACS） ...Objective： To evaluate the prognosis effect of Chinese herbal medicines（CHMs） for benefiting qi and activating blood circulation adjunctive to conventional treatment in patients with acute coronary syndrome（ACS） after percutaneous coronary intervention（PCI）. Methods： A total of 702 patients with ACS who underwent PCI were enrolled and randomly assigned to receive conventional treatment plus CHMs for benefiting qi and activating blood circulation（treatment group, 351 cases） or conventional treatment alone（control group, 351 cases） for 6 months. Six months later, all patients received conventional treatment alone. Follow-ups were scheduled at 6th, 12 th, 18 th, 24 th month after enrollment in April 2008, and the final follow-up visit was during September 2011 and November 2011. The primary endpoint was the composite of cardiac death, nonfatal myocardial infarction or revascularization（PCI or coronary artery bypass grafting）; and the secondary endpoint was the composite of re-admission for ACS, congestive heart failure, nonfatal stroke or other thrombus events. Results： A total of 621（88.59%） patients completed 35.4±3.8 months follow-up, while 80（11.41%） patients withdrew from the trial（41 in the treatment group and 39 in the control group）. The incidence of primary endpoint was 5.7%（20 patients） in the treatment group versus 10.86%（38 patients） in the control group [relative risk（RR）： 0.53; 95% confidence interval（CI）： 0.30, 0.88; P=0.013; absolute risk reduction（ARR）： –0.052, 95% CI： –0.06, 0.01]. The incidence of secondary endpoint was 5.98%（21 patients） in the treatment group versus 10.28%（36 patients） in control group（RR： 0.58, 95% CI： 0.33, 0.97, P=0.037; ARR： –0.043, 95% CI： 0.06, 0.01）. Most of the primary and secondary endpoints were occurred in 18 months（84.50% in the treatment group versus 78.10% in the control group）. Conclusion： CHMs for benefiting qi and activating blood circulation adjunctive to conventional treatment improved clinical outcomes for patients with ACS after PCI in long-term follow-up.展开更多
Naoxintong Capsule（脑心通胶囊,NXTC）is derived from the classic formula Buyang Huanwu Decoction（补阳还五汤）by WANG Qing-ren of the Qing Dynasty.Based on the concept of＂concurrent treatment on Nao（Brain）and Xin（...Naoxintong Capsule（脑心通胶囊,NXTC）is derived from the classic formula Buyang Huanwu Decoction（补阳还五汤）by WANG Qing-ren of the Qing Dynasty.Based on the concept of＂concurrent treatment on Nao（Brain）and Xin（Heart）＂（Nao Xin Tong Zhi）proposed by Prof.ZHAO Bu-chang,activating blood circulation and dredging collaterals herbs were supplemented to the classic formula.NXTC is composed of Astragalus membranaceus（Fisch.）Bge.展开更多
The diagnostic criterion of blood stasis syndrome（BSS） established in 1986 is a milestone in BSSdifferentiation of Chinese medicine （CM）. However,different disease has its own characteristics in BSS,thus establish...The diagnostic criterion of blood stasis syndrome（BSS） established in 1986 is a milestone in BSSdifferentiation of Chinese medicine （CM）. However,different disease has its own characteristics in BSS,thus establishing a BBS criterion of disease-syndromecombination has significance in clinical and basicstudies. BSS is the most common syndrome typeof CM in coronary heart disease （CHD）, but thereis not diagnostic criterion of BSS for CHD based ondisease-syndrome combination to date.展开更多
基金Supported by Beijing Municipal Science and Technology Project(Capital Characteristic Clinic Project,No.Z171100001017106)Beijing Municipal Science and Technology Project"Ten Disease and Ten Medicine"(No.Z171100001717016)。
文摘Background:The incidence of cognitive impairment(CI)is gradually increasing,which has attracted more attention from medical researchers worldwide.Definitive mechanisms of pathogenesis remain elusive,and there are few medications that have been proven effective for CI.The utilization of Chinese herbal medicine has shown positive therapeutic effects for a broad spectrum of diseases,including CI.Objective:The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules(GLJC,龟龄集胶囊)in treating mild-to-moderate CI with Shen(Kidney)and marrow deficiency syndrome.Methods:This is a randomized,double-blind,positive-controlled,multicenter clinical trial with a noninferiority design that included 348 participants randomly divided into an experimental arm and an active comparator arm.Individuals in the experimental arm(174 cases)took 0.6 g of GLJC once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day.Individuals in the active comparator arm(174 cases)took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day.The intervention period included two sessions over 24 weeks.The primary outcome be the effectiveness of GLJC on cognitive improvement after 24 weeks of treatment,which was defined as an increase in the Mini Mental State Examination(MMSE)and Montreal Cognitive Assessment(MoCA)Scale.The secondary outcomes were improvement in independence,daily living ability,and Chinese medicine(CM)syndrome,which were measured with the Alzheimer’s disease Rating Scale-Cognitive Project(ADAS-Cog),Clinical Dementia Rating(CDR)Total Score,Activities of Daily Living(ADL)Total Score and the Chinese Medicine Symptom Scale(CM-SS),respectively.Serum acetylcholine,acetylcholinesterase,bax and bcl-2 were monitored to explore the mechanism of GLJC on CI.In addition,safety measures,including vital signs,electrocardiography,laboratory indicators(full blood count,kidney and liver function tests,routine urine test and routine stool test)and adverse events,were also recorded.Discussion:The purpose of this trial is to evaluate the efficacy and safety of GLJC in patients with mild-to-moderate CI with kidney and marrow deficiency syndrome.If successful,the results would provide a viable treatment for patients with mild-to-moderate CI.
基金Supported by the National Natural Science Foundation of China(No.81473547,No.81673829)Young Scientists Training Program of Beijing University of Chinese Medicine(No.BUCM-YSTP-2019001)Cooperation Project of Beijing University of Chinese Medicine and Kunming Longjin Pharmaceutical(No.BUCM-YNLJ-2018001)。
文摘Objective:To investigate the shared mechanisms of scutellarin in angina pectoris(AP)and ischemic stroke(IS)treatment.Methods:A network pharmacology approach was used to detect the potential mechanisms of scutellarin in AP and IS treatment by target prediction,protein-protein interaction(PPI)data collection,network construction,network analysis,and enrichment analysis.Furthermore,molecular docking simulation was employed to analyze the interaction between scutellarin and core targets.Results:Two networks were established,including a disease-target network and a PPI network of scutellarin targets against AP and IS.Network analysis showed that 14 targets,namely,AKT1,VEGFA,JUN,ALB,MTOR,ESR1,MAPK8,HSP90 AA1,NOS3,SERPINE1,FGA,F2,FOXO3,and STAT1,might be the therapeutic targets of scutellarin in AP and IS.Among them,NOS3 and F2 were recognized as the core targets.Additionally,molecular docking simulation confirmed that scutellarin exhibited a relatively high potential for binding to the active sites of NOS3 and F2.Furthermore,enrichment analysis indicated that scutellarin might exert a therapeutic role in both AP and IS by regulating several important pathways,such as coagulation cascades,mitogen-activated protein kinase(MAPK)signaling pathway,phosphatidylinositol 3 kinase(PI3 K)/protein kinase B(Akt)/mammalian target of rapamycin(m TOR)signaling pathway,Toll-like receptor signaling pathway,hypoxia inducible factor-1(HIF-1)signaling pathway,forkhead box O(Fox O)signaling pathway,tumor necrosis factor(TNF)signaling pathway,adipocytokine signaling pathway,insulin signaling pathway,insulin resistance,and estrogen signaling pathway.Conclusions:The shared underlying mechanisms of scutellarin on AP and IS treatment might be strongly associated with its vasorelaxant,anticoagulant,anti-inflammatory,and antioxidative effects as well as its effect on improving lipid metabolism.
文摘Ginkgo(Ginkgo biloba L.)is aperennial deciduous tree of the Ginkgoaceae family,and its seeds(ginkgo nut)and leaves have high medicinal values.G.biloba was firstly recorded in Materia Medica in Shaoxin Medica;previous texts on Materia Medica have mostly listed ginkgo nuts.
基金Supported by the Eleventh Five-Year Plan for Science and Technology Research of China(No.2006BA104A01)National Program on Key Basic Research Project of China(No.2015CB554402)
文摘Objective： To evaluate the prognosis effect of Chinese herbal medicines（CHMs） for benefiting qi and activating blood circulation adjunctive to conventional treatment in patients with acute coronary syndrome（ACS） after percutaneous coronary intervention（PCI）. Methods： A total of 702 patients with ACS who underwent PCI were enrolled and randomly assigned to receive conventional treatment plus CHMs for benefiting qi and activating blood circulation（treatment group, 351 cases） or conventional treatment alone（control group, 351 cases） for 6 months. Six months later, all patients received conventional treatment alone. Follow-ups were scheduled at 6th, 12 th, 18 th, 24 th month after enrollment in April 2008, and the final follow-up visit was during September 2011 and November 2011. The primary endpoint was the composite of cardiac death, nonfatal myocardial infarction or revascularization（PCI or coronary artery bypass grafting）; and the secondary endpoint was the composite of re-admission for ACS, congestive heart failure, nonfatal stroke or other thrombus events. Results： A total of 621（88.59%） patients completed 35.4±3.8 months follow-up, while 80（11.41%） patients withdrew from the trial（41 in the treatment group and 39 in the control group）. The incidence of primary endpoint was 5.7%（20 patients） in the treatment group versus 10.86%（38 patients） in the control group [relative risk（RR）： 0.53; 95% confidence interval（CI）： 0.30, 0.88; P=0.013; absolute risk reduction（ARR）： –0.052, 95% CI： –0.06, 0.01]. The incidence of secondary endpoint was 5.98%（21 patients） in the treatment group versus 10.28%（36 patients） in control group（RR： 0.58, 95% CI： 0.33, 0.97, P=0.037; ARR： –0.043, 95% CI： 0.06, 0.01）. Most of the primary and secondary endpoints were occurred in 18 months（84.50% in the treatment group versus 78.10% in the control group）. Conclusion： CHMs for benefiting qi and activating blood circulation adjunctive to conventional treatment improved clinical outcomes for patients with ACS after PCI in long-term follow-up.
文摘Naoxintong Capsule（脑心通胶囊,NXTC）is derived from the classic formula Buyang Huanwu Decoction（补阳还五汤）by WANG Qing-ren of the Qing Dynasty.Based on the concept of＂concurrent treatment on Nao（Brain）and Xin（Heart）＂（Nao Xin Tong Zhi）proposed by Prof.ZHAO Bu-chang,activating blood circulation and dredging collaterals herbs were supplemented to the classic formula.NXTC is composed of Astragalus membranaceus（Fisch.）Bge.
文摘The diagnostic criterion of blood stasis syndrome（BSS） established in 1986 is a milestone in BSSdifferentiation of Chinese medicine （CM）. However,different disease has its own characteristics in BSS,thus establishing a BBS criterion of disease-syndromecombination has significance in clinical and basicstudies. BSS is the most common syndrome typeof CM in coronary heart disease （CHD）, but thereis not diagnostic criterion of BSS for CHD based ondisease-syndrome combination to date.
